Top

Published in:

Open Access 08-02-2024 | Migraine | ORIGINAL RESEARCH

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Authors: Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, Antonio Russo, Piero Barbanti, Grazia Sances, Sabina Cevoli, Renata Rao, Carlo Lovati, Anna Ambrosini, Carlotta Buzzoni, Federico Battisti, Laura Vatteone, Steffy Martin Luther King, Federico Torelli

Published in: Neurology and Therapy | Issue 2/2024

Abstract

Background

Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting.

Methods

This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020. Patient data for monthly migraine days (MMDs) and MMDs with acute medication intake were obtained by medical chart reviews. Information on patient-reported outcomes (using the Migraine Disability Assessment [MIDAS] questionnaire and Headache Impact Test 6 [HIT-6] questionnaire) and on the use of healthcare resources were also collected. The time points of interest were 1, 3, 6, 9, 12 months after the initiation of galcanezumab, and the most recent time point available during follow-up.

Results

A total of 207 patients were enrolled in the study. Starting from month 3 after treatment initiation, more than half of the patients presented at least a 50% reduction in MMDs, and approximately one-third of non-responders at month 3 became responders at month 6. From month 3 to month 12, MMDs decreased on average by 10 days. Headache impact and disability, as well as migraine-associated health resource utilization decreased significantly during the treatment period. A positive significant association among the three dimensions of clinical burden (MMDs, MIDAS and days of acute medication intake) was also observed.

Conclusion

The results of this Italian real-world study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response among patients over different migraine-related burdens. The use of healthcare resources was also remarkably reduced.

Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–15. https://doi.org/10.1016/j.jns.2016.11.071.CrossRefPubMed

Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. https://doi.org/10.1016/j.aprim.2021.102208.CrossRefPubMed

Doane MJ, Vo P, Bilitou A et al. Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use. Abstract no. [MTIS2018-083]. In: MTIS 2018 abstracts. Cephalalgia. 2018;38(1S). https://journals.sagepub.com/doi/pdf/10.1177/0333102418789865.

Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14. https://doi.org/10.1038/s41582-021-00509-5.CrossRefPubMedPubMedCentral

Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18:96. https://doi.org/10.1186/s10194-017-0807-1.CrossRefPubMedPubMedCentral

European Medicines Agency. Emgality. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/emgality. Accessed 13 Jan 2023.

Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020;37:2034–49. https://doi.org/10.1007/s12325-020-01319-9.CrossRefPubMedPubMedCentral

Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol. 2020;27:609–18. https://doi.org/10.1111/ene.14114.CrossRefPubMed

Mulleners WM, Kim B-K, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–25. https://doi.org/10.1016/S1474-4422(20)30279-9.CrossRefPubMed

10.

Vernieri F, Brunelli N, Marcosano M, et al. Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol. 2023;30:224–34. https://doi.org/10.1111/ene.15563.CrossRefPubMed

11.

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. https://doi.org/10.1177/0333102417738202.

12.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–8. https://doi.org/10.1001/jamaneurol.2018.1212.CrossRefPubMedPubMedCentral

13.

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–54. https://doi.org/10.1177/0333102418779543.CrossRefPubMed

14.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–21. https://doi.org/10.1212/WNL.0000000000006640.CrossRefPubMedPubMedCentral

15.

Altamura C, Brunelli N, Marcosano M, et al. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022;269:5848–57. https://doi.org/10.1007/s00415-022-11226-4.CrossRefPubMedPubMedCentral

16.

Vernieri F, Altamura C, Brunelli N, et al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022;29:1198–208. https://doi.org/10.1111/ene.15197.CrossRefPubMed

17.

Vernieri F, Altamura C, Brunelli N, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https://doi.org/10.1186/s10194-021-01247-1.CrossRefPubMedPubMedCentral

18.

Kwon S, Gil Y-E, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42:705–14. https://doi.org/10.1177/03331024221076481.CrossRefPubMed

19.

Schwedt TJ, Kuruppu DK, Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021;22:15. https://doi.org/10.1186/s10194-021-01230-w.CrossRefPubMedPubMedCentral

20.

Barbanti P, Aurilia C, Egeo G, et al. Late response to Anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. Neurology. 2023;101(11):482-8. https://doi.org/10.1212/WNL.0000000000207292.

21.

Ambrosini A, Estemalik E, Pascual J, et al. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). J Manag Care Spec Pharm. 2022;28:645–56. https://doi.org/10.18553/jmcp.2022.21375.CrossRefPubMed

22.

Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2022;42:326–34. https://doi.org/10.1177/03331024211046617.CrossRefPubMed

23.

Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22:154. https://doi.org/10.1186/s10194-021-01363-y.CrossRefPubMedPubMedCentral

24.

Iannone LF, Fattori D, Benemei S, et al. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29:1505–13. https://doi.org/10.1111/ene.15260.CrossRefPubMed

25.

Silvestro M, Tessitore A, Orologio I, et al. Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain. 2022;23:69. https://doi.org/10.1186/s10194-022-01436-6.CrossRefPubMedPubMedCentral

26.

Barbanti P, Egeo G, Aurilia C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138. https://doi.org/10.1186/s10194-022-01498-6.CrossRefPubMedPubMedCentral

27.

Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16(7):934. https://doi.org/10.3390/ph16070934.CrossRefPubMed

28.

Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023;24(1):16. https://doi.org/10.1186/s10194-023-01552-x.CrossRefPubMedPubMedCentral

Title: Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)
Authors: Fabrizio Vernieri
Luigi Francesco Iannone
Simona Guerzoni
Antonio Russo
Piero Barbanti
Grazia Sances
Sabina Cevoli
Renata Rao
Carlo Lovati
Anna Ambrosini
Carlotta Buzzoni
Federico Battisti
Laura Vatteone
Steffy Martin Luther King
Federico Torelli
Publication date: 08-02-2024
Publisher: Springer Healthcare
Keywords: Migraine
Galcanezumab
Headache
Published in: Neurology and Therapy / Issue 2/2024
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-024-00582-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Clinical and Polysomnographic Characteristics of Adult Patients with Suspected Obstructive Sleep Apnea from Different Sleep Clinics at a Single Tertiary Center

Monitoring of Perioperative Microcirculation Dysfunction by Near-Infrared Spectroscopy for Neurological Deterioration and Prognosis of Aneurysmal Subarachnoid Hemorrhage: An Observational, Longitudinal Cohort Study

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

Textbook Outcomes Among Patients with Aneurysmal Subarachnoid Hemorrhage Following Endovascular Treatment

Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study

Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)